Competitive inhibitors of AKT (afuresertib, capivasertib, ipatasertib, uprosertib) and allosteric inhibitors (MK-2206, TAS-117, ARQ092/miransertib, BAY1125976) are being studied in preclinical and clinical settings.[22] Capivasertib is the world’s first FDA-approved AKT inhibitor that is used in combination with fulvestrant to treat breast cancer patients who meet specific criteria (2023-11-17). Here, AKT1 is linked to breast carcinoma.